key: cord-1029237-avmfz0z7 authors: Keeton, R.; Tincho, M. B.; Ngomti, A.; Baguma, R.; Benede, N.; Suzuki, A.; Khan, K.; Cele, S.; Bernstein, M.; Karim, F.; Madzorera, S. V.; Moyo-Gwete, T.; Mennen, M.; Skelem, S.; Adriaanse, M.; Mutithu, D.; Aremu, O.; Stek, C.; du Bruyn, E.; Van Der Mescht, M.; de Beer, Z.; de Villiers, T. R.; Bodenstein, A.; van den Berg, G.; Mendes, A.; Strydom, A.; Venter, M.; Grifoni, A.; Weiskopf, D.; Sette, A.; Wilkinson, R. J.; Bekker, L.-G.; Gray, G.; Ueckermann, V.; Rossouw, T.; Boswell, M. T.; Bihman, J.; Moore, P.; Sigal, A.; Ntusi, N. A. B.; Burgers, W. A.; Riou, C. title: SARS-CoV-2 spike T cell responses induced upon vaccination or infection remain robust against Omicron date: 2021-12-28 journal: nan DOI: 10.1101/2021.12.26.21268380 sha: 2c4e317cde2cf6324ebb23a2deb961b7632ab66e doc_id: 1029237 cord_uid: avmfz0z7 The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to escape from the neutralizing antibody responses, and reducing vaccine protection from infection. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. We assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients (n = 70). We found that 70-80% of the CD4 and CD8 T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations. Additionally, in Omicron-infected hospitalized patients (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those found in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49). These results demonstrate that despite Omicron's extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, cross-recognises the variant. Well-preserved T cell immunity to Omicron is likely to contribute to protection from severe COVID-19, supporting early clinical observations from South Africa. The SARS-CoV-2 Omicron variant has multiple Spike (S) protein mutations that contribute to escape from the neutralizing antibody responses, and reducing vaccine protection from infection. The extent to which other components of the adaptive response such as T cells may still target Omicron and contribute to protection from severe outcomes is unknown. We assessed the ability of T cells to react with Omicron spike in participants who were vaccinated with Ad26.CoV2.S or BNT162b2, and in unvaccinated convalescent COVID-19 patients (n = 70). We found that 70-80% of the CD4 and CD8 T cell response to spike was maintained across study groups. Moreover, the magnitude of Omicron cross-reactive T cells was similar to that of the Beta and Delta variants, despite Omicron harbouring considerably more mutations. Additionally, in Omicron-infected hospitalized patients (n = 19), there were comparable T cell responses to ancestral spike, nucleocapsid and membrane proteins to those found in patients hospitalized in previous waves dominated by the ancestral, Beta or Delta variants (n = 49). These results demonstrate that despite Omicron's extensive mutations and reduced susceptibility to neutralizing antibodies, the majority of T cell response, induced by vaccination or natural infection, crossrecognises the variant. Well-preserved T cell immunity to Omicron is likely to contribute to protection from severe COVID-19, supporting early clinical observations from South Africa. The newest SARS-CoV-2 variant of concern, designated Omicron 1 ,was described on 26 November 2021 from sequences from Botswana, Hong Kong and South Africa 2 . Omicron is responsible for the current surge of infections in South Africa, and is becoming globally dominant. With over 30 mutations in the spike protein, a substantial ability to evade the neutralizing antibody response has been described [3] [4] [5] [6] . This associates with greater capacity for reinfection 7 , as well as lower early estimates of vaccine effectiveness against symptomatic disease 8,9 . SARS-CoV-2-specific T cells play a key role in modulating COVID-19 severity 10-12 , and provide protective immunity in the context of suboptimal antibody titers 13 . Given Omicron's extensive ability to escape antibody responses, we determined whether T cells generated in response to vaccination or previous SARS-CoV-2 infection could cross-recognize Omicron. We examined T cell responses in participants who had received one or two is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint Convalescent donors were examined a median of 1.4 months (interquartile range [IQR]: 1.3-6 months) after mild or asymptomatic infection. More than 85% of vaccinees generated a T cell response to vaccination, measured 22-32 days after the last dose (Fig. 1b) . Both vaccination and infection induced spike-specific CD4 T cell responses, while a CD8 response was less consistently detected (Fig. 1c ). We measured cytokine production (IFN-γ, IL-2 and TNF-α) by intracellular cytokine staining in response to peptide pools covering the full Wuhan-1 spike protein (ancestral) and the Omicron spike ( Fig. 1d and Extended Data Fig 1a) . CD4 T cell frequencies to Omicron spike were consistently and significantly lower than ancestral spike in all groups tested (Fig. 1e) . This translated to a median decrease of 14-30% of the CD4 response to Omicron, as demonstrated by foldchange (Fig. 1f ). Similar results were observed for the CD8 T cell response (Fig. 1g- there were also no differences in the polyfunctional profiles between ancestral and Omicron spike for either CD4 or CD8 T cells (Extended Data Fig. 2c and 3c ), indicating the absence of a functional deficit in cross-reactive Omicron T cell responses. We also compared Omicron spike responses to other variants of concern in Ad26.CoV2.S vaccinees, by testing spike peptide pools corresponding to the viral sequences of the Beta and Delta strains (Extended Data Fig. 4a ). There were no significant differences in cross-reactive CD4 and CD8 T cell responses between Beta, Delta and Omicron (Extended Data Fig. 4b) , with the exception of a greater decrease in the Omicron CD4 response compared to Beta in recipients of two doses of Ad26.COV2.S. Of note, while prior SARS-CoV-2 infection in vaccinees associated with a higher frequency of spikespecific T cells (Extended Data Fig. 5a) , it had no impact on Omicron cross-reactivity (Extended Data Fig. 5b ). Overall, these results show that CD4 and CD8 T cell recognition of Omicron spike is largely preserved compared to the ancestral strain, and is similar to other variants of concern carrying three times fewer mutations. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint The SARS-CoV-2 epidemic in South Africa has been characterized by four virologically distinct infection waves (Fig. 2b ). This enabled us to compare T cell responses in patients from the current fourth epidemic wave, dominated by Omicron, with those infected in prior waves dominated by ancestral (Wave 1, n =17), Beta (Wave 2, n =16) and Delta (Wave 3, n =16) variants (Fig. 2a ). In addition to extensive mutations in spike, Omicron has 20 additional mutations in other proteins which could also result in T cell escape. Therefore, we measured the frequency of CD4 and CD8 T cells to ancestral spike (S), nucleocapsid (N) and membrane (M) proteins, all major targets of the T cell response 16 . We studied SARS-CoV-2-infected patients who were hospitalized with COVID-19 (Fig. 2a) . These recently hospitalized patients, is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint Proportion of participants exhibiting an ancestral spike-specific CD4 T cell response after vaccination with one or two doses of Ad26.COV2.S or two doses of BNT162b2. c, Profile of the ancestral spike-specific T cell response in vaccinees and convalescent individuals. d, Representative examples of IFN-γ production in response to ancestral and Omicron spike in two individuals who received two doses of Ad26.COV2.S. e,g, Frequency of spike-specific CD4 (e) and CD8 T cells (g) producing any of the measured cytokines (IFN-γ, IL-2 or TNF-α) in response to ancestral and Omicron spike peptide pools. Bars represent median of responders. Differences between SARS-CoV-2 variants were calculated using a Wilcoxon paired t-test. f, h, Fold change in the frequency of spike-specific CD4 (f) and CD8 T cells (h) between ancestral and Omicron spike responses. Bars represent medians. No significant differences were observed between groups using a Kruskal-Wallis test with Dunn´s multiple comparisons post-test. The number of participants included in each analysis is indicated on the graphs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint Wave: is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. . c, Comparison of the polyfunctional profile between ancestral and Omicron spike-specific CD4 T cells including all CD4 T cell responding participants, irrespective of their clinical grouping. The medians and IQR are shown. Each response pattern (i.e., any possible combination of IFN-γ, IL-2 or TNF-α expression) is color-coded, and data are summarized in the pie charts. No significant differences were observed between pies using a permutation test. The number of participants included in each analysis is indicated on the graphs. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint Extended Data Fig. 3 : Fig. 3 : Polyfunctional profiles of SARS-CoV-2-specific CD8 T cells after vaccination and in unvaccinated convalescent volunteers. a, b, Comparison of the polyfunctional profile of ancestral (a) and Omicron (b) spike-specific CD8 T cells between the four groups (Ad26.COV2.S-one dose, Ad26.COV2.S-two doses, BNT162b2-two doses and unvaccinated convalescent COVID-19 volunteers). c, Comparison of the polyfunctional profile between ancestral spike and Omicron spike-specific CD8 T cells including all CD8 T cell responding participants, irrespective of their clinical grouping. The medians and IQR are shown. Each response pattern (i.e., any possible combination of IFN-γ, IL-2 or TNF-α expression) is color-coded, and data are summarized in the pie charts. No significant differences were observed between pies using a permutation test. The number of participants included in each analysis is indicated on the graphs. Ancestral spike is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. Pies depict the proportion of participants exhibiting a detectable CD8 T cell response. Bars represent medians. Statistical differences were calculated using a Mann-Whitney test. b, Fold change in the frequency of spike-specific CD4 T cells between ancestral and Omicron spike responses in the three vaccine groups. Bars represent medians. Statistical differences were calculated using a Mann-Whitney test. The number of participants included in each analysis is indicated on the graphs. . CC-BY 4.0 International license It is made available under a perpetuity. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint ranging from 1 to 7 months. The demographic and clinical characteristics of convalescent volunteers are summarized in Supplementary Table 2. Sixty-eight hospitalized COVID-19 patients were included in this study. These participants were grouped according to the time of their hospitalization, reflecting four distinct infection waves in South Africa, each dominated by a different SARS-CoV-2 strain (Fig. 2b) is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint individual peptides in the respective SARS-CoV-2 spike sequences, followed by sequential lyophilization steps, and resuspension in DMSO at 1 mg/mL. Pools were used at a final concentration of 1 µg/mL with an equimolar DMSO concentration in the non-stimulated control. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint diluted plasma. Antibody-virus mixtures were incubated for 1 h at 37 °C, 5% CO2. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint W.A.B, C.R. and R.K. designed the study. C.R. and W.A.B analyzed the data and wrote is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint The copyright holder for this this version posted December 28, 2021. ; https://doi.org/10.1101/2021.12.26.21268380 doi: medRxiv preprint Classification of omicron (B.1.1.529): SARS-CoV-2 variant of concern Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies SARS-CoV-2 omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection Considerable escape of SARS-CoV-2 Omicron to antibody neutralization Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa We are indebted to the participants who volunteered samples to this study. We thank Wesley van Hougenhouck-Tulleken for assistance with database management for the Pretoria COVID-19 study; Rajiev Ramlall and Jane Semugga for assistance with participant recruitment at Tshwane District Hospital. We thank Cathrine Scheepers and Josie Everatt for generous assistance with plotting lineage prevalence, and the